Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > $Value to Insiders from a Potential Buyout

<< Previous

Bullboard Posts

Next >>

Comment by Probosciseson Jan 10, 2023 7:06pm

205 Views

Post# 35214634

RE:RE:$Value to Insiders from a Potential Buyout

Yes, I mis-typed. I guess I'm not used to dealing with all those zeros. However, the calculated amounts for each insider should be accurate. If you think $4 or $5 billion or whatever is a more accurate buyout price then multiply by 2 or 2.5 or whatever. Subtracting off the option exercise price does not have a big effect.

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 22, 2024)